Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Bendamustine and Rituximab for Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT00547534Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Oct 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and bendamustine in Indolent Non-Hodgkin Lymphoma (INHL) and mantle cell lymphoma (MCL), sponsored by University of Rochester. Primary endpoint: Progression Free Survival at 2 Years. Started Oct 2007; status: completed.
02
Drugs
bortezomibbendamustine
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00547534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00547534.